Indication
Treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy
other than somatostatin analogues.
Medicine details
- Medicine name:
- cabozantinib (Cabozantinib Ipsen)
- SMC ID:
- SMC2860
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC